Special Populations Pharmacology

Prescribing medications isn't a one-size-fits-all endeavor. For pregnant individuals, children, and older adults, physiological differences drastically alter how drugs are absorbed, distributed, metabolized, and excreted. Mastering pharmacology for these special populations is essential to avoid harm, maximize efficacy, and navigate complex risk-benefit calculations that define safe clinical practice.

Pharmacokinetic Shifts and Teratogenic Risk in Pregnancy

Pregnancy induces profound physiological changes that systematically alter pharmacokinetics—the body's handling of a drug. A key change is an increased volume of distribution due to a 40-50% rise in plasma volume and increased total body water. This dilution effect often leads to lower plasma concentrations for water-soluble drugs, potentially requiring adjusted dosing. Concurrently, renal clearance is enhanced by up to 50% because of increased renal blood flow and glomerular filtration rate. This accelerated excretion reduces the plasma concentration of drugs eliminated by the kidneys, such as many antibiotics (e.g., penicillins, cephalosporins) and lithium, necessitating careful monitoring and possible dose increases.

Beyond pharmacokinetics, the paramount concern is teratogenicity, the ability of a drug to cause fetal malformations. Risk assessment follows a risk-versus-benefit framework, categorizing drugs from known teratogens (e.g., isotretinoin, warfarin, valproic acid) to those generally considered safe. The period of greatest risk is often organogenesis, typically weeks 3-8 post-conception. For example, ACE inhibitors are contraindicated in the second and third trimesters due to risks of fetal renal damage, but the risk profile during early organogenesis is less clear, illustrating the nuanced decision-making required. The goal is to use the fewest medications at the lowest effective doses for the shortest duration, while never withholding necessary treatment for serious maternal conditions.

Pediatric Dosing and Developmental Pharmacology

Pediatric dosing is fundamentally different from adult dosing. Two primary methods are used: dosing by weight (mg/kg) and dosing by body surface area (mg/m²). Weight-based dosing is common for infants and children, while body surface area (BSA) dosing, calculated using formulas like the Mosteller equation ($BSA(m^2)=\sqrt{\frac{height(cm)\times weight(kg)}{3600}}$), is often preferred for chemotherapeutic agents and drugs with a narrow therapeutic index, as it better correlates with metabolic rate.

These precise calculations are critical because of developmental immaturity. In neonates (first 28 days of life) and young infants, immature hepatic function means phase I reactions (like cytochrome P450 activity) and phase II conjugation (like glucuronidation) are significantly reduced. This can lead to prolonged drug half-lives and toxicity, as seen with chloramphenicol causing "gray baby syndrome." Similarly, immature renal function, with low glomerular filtration and tubular secretion, reduces clearance of renally excreted drugs like aminoglycosides and penicillins, requiring longer dosing intervals. As a child grows, organ function matures rapidly, necessitating frequent dose re-evaluations.

Geriatric Considerations: Polypharmacy and Altered Physiology

The geriatric population presents the challenge of polypharmacy, typically defined as the use of five or more medications. Polypharmacy increases the risk of drug-drug interactions, adverse drug reactions, non-adherence, and functional decline. A systematic approach involves conducting a "brown bag review" of all medications (prescribed, OTC, and supplements) at every visit and deprescribing any that are unnecessary or inappropriate.

A key tool for identifying inappropriate medications is the Beers Criteria, a regularly updated list of drugs that pose higher risks than benefits for adults 65 and older. Examples include long-acting benzodiazepines (e.g., diazepam) due to high risk of delirium and falls, and anticholinergic drugs like diphenhydramine, which can cause confusion and urinary retention. Using the Beers Criteria is a standard part of safe geriatric pharmacotherapy.

These concerns are compounded by age-related pharmacokinetic changes. Absorption may be slowed but is generally not clinically significant. Distribution changes due to increased body fat and decreased lean body mass and total body water: fat-soluble drugs (e.g., diazepam) have an increased volume of distribution and prolonged half-life, while water-soluble drugs (e.g., ethanol, lithium) have a decreased volume, leading to higher initial plasma concentrations. Hepatic metabolism often declines due to reduced liver mass and blood flow, and renal excretion decreases steadily after age 40 due to falling glomerular filtration rate (GFR), a change not reflected in serum creatinine alone due to decreased muscle mass. This necessitates routine estimation of creatinine clearance using formulas like Cockcroft-Gault to guide dosing of renally excreted drugs.

Common Pitfalls

1. Extrapolating Adult Doses to Children: Simply "downsizing" an adult dose is dangerous. Failing to use proper weight or BSA calculations, or not accounting for a child's specific developmental stage of hepatic or renal function, can lead to severe under-dosing or toxicity.

• Correction: Always use pediatric-specific dosing guidelines, calculate doses meticulously, and consider the child's age and organ maturation.

1. Overlooking Pregnancy in Women of Childbearing Age: Prescribing without considering the possibility of pregnancy, especially with known teratogens, is a critical error.

• Correction: Establish pregnancy status when clinically relevant, discuss contraception during therapy with high-risk drugs, and always weigh maternal benefit against fetal risk.

1. Relying on Serum Creatinine Alone in Older Adults: Assuming a "normal" serum creatinine indicates normal kidney function in a frail, low-muscle-mass older adult. This can lead to overdosing drugs like direct oral anticoagulants (DOACs), gabapentin, or antibiotics.

• Correction: Routinely estimate creatinine clearance (e.g., using the CKD-EPI equation) for any drug that is renally cleared in patients over 65.

1. Failing to Deprescribe: Continuously adding medications without stopping others leads to problematic polypharmacy.

• Correction: Make medication reconciliation a priority. For each drug, regularly ask: "Is this still necessary? Does the indication remain? Do the benefits still outweigh the risks?"

Summary

• Pregnancy alters pharmacokinetics significantly, with increased volume of distribution and renal clearance often requiring dose adjustments, while teratogenicity risk assessment is the cornerstone of any therapeutic decision.
• Pediatric dosing must be precise, using weight or body surface area calculations, and must account for immature hepatic and renal function in neonates, which prolongs the effects of many drugs.
• Geriatric patients are highly susceptible to polypharmacy and its complications. The Beers Criteria is an essential tool for identifying potentially inappropriate medications.
• Age-related pharmacokinetic changes, including reduced hepatic metabolism and renal excretion, are universal in older adults and mandate dose adjustments based on estimated renal function, not serum creatinine alone.